Centessa Pharmaceuticals — Investor Presentation (March 2022)
46 slides from Centessa Pharmaceuticals's investor presentation, Mar 30, 2022
Slide 1: Corporate Overview March 2022
Corporate Overview MARCH 2022
Slide 2: Disclaimer and forward-looking statements
This presentation has been prepared by Centessa Pharmaceuticals plc (the “Company”) for informational purposes only and not for any other purpose. This presentation does not contain all the information that is or may be material to investors or potential investors and should not be considered as adv
Slide 3: R&D innovation engine to deliver impactful medicines to patients
3 We are an R&D innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients
Slide 4: Centessa management team with deep R&D experience
Centessa management team with deep R&D experience 4 MARELLA THORELL Chief Accounting Officer THOMAS TEMPLEMAN PhD Chief Technology Officer DAVID CHAO PhD Chief Administrative Officer TIA BUSH Chief Quality Officer SAURABH SAHA MD PhD Chief Executive Officer ANTOINE YVER MD MSc EVP & Chairman of Deve
Slide 5: 4 x 24: registrational programs goal and current portfolio
“4 x 24”: Our goal is to have 4 registrational programs in 2024 5 Substantial portfolio of programs targeting multi-billion dollar markets Lixivaptan in Autosomal Dominant Polycystic Kidney Disease SerpinPC in Hemophilia (Hemophilia B for initial registrational trial) 1 REGISTRATIONAL (Programs in r
Slide 6: Asset, disease, reason to believe, market validation
Asset Disease Reason to believe Market validation Lixivaptan ADPKD Potential to avoid safety issues associated with the only approved drug (product-specific tox with black box / REMS) $770M 2021 US sales for Otsuka’s flagship product, JYNARQUE®, only one approved for ADPKD SerpinPC Hemophilia A and
Slide 7: Portfolio spans rare disease programs and IO platform
Our portfolio spans high value Rare Disease programs and IO platform 7 • Exciting Rare Disease pipeline targeting large opportunities with high unmet patient need RARE DISEASE Note: Alpha-1 Antitrypsin Deficiency prevalence based on estimate of PiZZ individuals in the US Sources: Acquavella et al, 2
Slide 8: Upcoming 2022 catalysts with cash runway into early 2024
Upcoming 2022 catalysts with cash runway into early 2024 $595 million cash and cash equivalents as of December 31, 2021 Note: Cash runway does not include potential draws on the remaining available tranches under the Oberland facility. Currently $75m drawn under facility. 2022 data • LB101 in Solid
Slide 9: Lixivaptan in ADPKD
Lixivaptan in ADPKD 9
Slide 10: Lixivaptan uniquely positioned for differentiated profile in ADPKD
Lixivaptan is uniquely positioned to deliver a differentiated profile in ADPKD 10 • ~140,000 ADPKD patients in the US and only one FDA approved product (tolvaptan), which has a boxed warning about its serious and potentially fatal liver injury LARGE RARE DISEASE MARKET WITH HIGH UNMET NEED FOR A SAF
Slide 11: ADPKD market is a multi-billion dollar rare disease opportunity
The ADPKD market represents a multi-billion dollar rare disease opportunity 11 0 20 40 60 80 100 120 140 U S P a ti e n ts ( 0 0 0 ’s ) Sources: Willey et al., 2019; primary market research 1. Otsuka Holdings FY2021 Financial Results Presentation 2. Evaluate Pharma ~ 140,000 ADPKD patients in the US
Slide 12: Potential to avoid liver risk with unique structure and chemistry
Potential to avoid liver risk with unique structure and differential chemistry 12 mitochondrion hepatocyte bile salts BSEP MRP4 DM-4103 tolvaptan DM-4103 is a tolvaptan-specific metabolite believed to cause liver toxicity Chemical species Tolvaptan DM-4103 DM-4107 Lixivaptan 141624 138451 138758 Par
Slide 13: Drug-induced liver injury observed in tolvaptan clinical trials
Drug-induced liver injury observed in tolvaptan clinical trials 12 months with monthly monitoring Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH plots) Hy’s Law Quadrant* Tolvaptan TEMPO Study1 Tolvaptan REPRISE Study2 36 months with quarterly monitoring T o ta l b il ir u b in ( xU LN ) P
Slide 14: No liver tox observed with lixivaptan in tolvaptan-intolerant subjects
No liver tox observed to date with lixivaptan in tolvaptan-intolerant subjects Young subject with ADPKD developed DILI on each of three unsuccessful attempts to initiate tolvaptan. Initial tolvaptan experience Lixivaptan did not cause any signs of liver toxicity in this highly susceptible subject du
Slide 15: Urine osmolality is key physiologic marker for drug activity
Urine osmolality is the key physiologic marker for drug activity in ADPKD As expected, lixivaptan is associated with suppression of urine osmolality (Uosm) Tolvaptan (TEMPO Study1) Lixivaptan (ELiSA Study, PA-1022) 81% 83% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Share of ADPKD Patients Meeting Target
Slide 16: Ongoing ACTION Phase 3 trial for lixivaptan in ADPKD
Ongoing ACTION Phase 3 clinical trial for lixivaptan in ADPKD Three post-week 52 measurements for Part 1 Baseline measurement Screening Titration Part 1 Double-blind treatment period (52 weeks) 2:1 randomization of ~1,350 subjects Three post-week 52 measurements for Part 2 No Drug (4 weeks) Lixivapt
Slide 17: Lixivaptan expected to have limited potential competition
Lixivaptan is expected to have limited potential competition • JYNARQUE® Orange Book exclusivity through April 2030 • Lixivaptan recent patent with expiration in 2038 before considering patent term extensions or adjustments • Sanofi announced the discontinuation of the venglustat ADPKD program in Ju
Slide 18: SerpinPC in Hemophilia
SerpinPC in Hemophilia 18
Slide 19: SerpinPC potential to shift Hemophilia B treatment paradigm
SerpinPC has the potential to shift Hemophilia B treatment paradigm 19 • Human genetic target validation in individuals who co-inherit Factor V Leiden mutation and either FVIII or FIX mutations reinforced with positive proof-of-concept Phase 2 data GENETIC VALIDATION AND CLINICAL PROOF OF CONCEPT FO
Slide 20: SerpinPC unique MoA supported by human genetics
SerpinPC is believed to have a unique MoA supported by human genetics 20 Extrinsic Tenase Intrinsic Tenase Prothrombinase Prothrombin Thrombin SerpinPC APC Protein C Feedback Loop SerpinPC reduces levels of circulating APC (1), thereby prolonging activity of prothrombinase (2) and directly increasin
Slide 21: SerpinPC showed reductions in bleeding rates in Phase 2a
SerpinPC showed promising reductions in bleeding rates and was observed to be well-tolerated in the Phase 2a study Across all dose levels: • No thrombosis • No instances of sustained elevations in D-dimer • 1 moderate skin reaction led to withdrawal of a subject with history of a skin disorder • Two
Slide 22: Two registrational trials planned in Hemophilia B
Two registrational trials planned to start in 2H 2022 in Hemophilia B Hem B without inhibitors Part 1 Randomized dose-justification (24 weeks on treatment, n = 60) Observation period SerpinPC Multiple cohorts with different dosing frequency Hem B without inhibitors Part 2 Expansion phase at selected
Slide 23: LB101 & LB201 in Solid Tumors
23 LB101 & LB201 in Solid Tumors
Slide 24: LockBody programs aim to redefine immuno-oncology treatment
LockBody® programs aim to redefine immuno-oncology treatment 24 • LockBody® mechanism aims to bypass typical “sink” effect, minimize peripheral toxicity, and drive maximal effector function activity, such as CD47, directly into the tumor DESIGNED TO ADDRESS IMMUNO-ONCOLOGY THERAPY CHALLENGES • Effec
Slide 25: LB101 designed for anti-PD-L1 plus CD47 activity in TME
25 PD-L1 Domains Fully human Locked CD47 Domains Ultrahumanized Natural hinge clipping in tumors IgG1 Fc Exposed CDRs Locked Unlocked LB101 is designed to allow for anti-PD-L1 activity plus CD47 activity in the TME
Slide 26: In vitro data showed effector function locking
In vitro data using Her2xCD47 LockBody® demonstrated effector function locking 26 Locked form: No measurable binding to CD47 Unlocked form: Clear, high-affinity, concentration-dependent binding huCD47-ECD-His at 400 nM huCD47-ECD-His at 200 nM huCD47-ECD-His at 100 nM huCD47-ECD-His at 50 nM huCD47-
Slide 27: In vivo data: well tolerated with antibody-like PK
In vivo data showed Her2xCD47 LockBody® was generally well tolerated and stable, with antibody-like pharmacokinetics (PK) 27 Her2xCD47 LockBody® • Long, mAb-like distribution • Up to 100-fold increase in AUC • No evidence of target-driven clearance, no anaemia, no reticulocyte amplification CD47 IgG
Slide 28: LockBody development plan and upcoming milestones
LockBody® development plan and upcoming milestones Plan to present foundational preclinical data at ASCO (June 2022) evaluating the activity and tolerability of LB101 monotherapy in a hPD-L1+ syngeneic model in mice, in comparison with atezolizumab Plan to submit an IND for LB101 (PD-L1xCD47) in lat
Slide 29: ZF874 in AATD
ZF874 in AATD 29
Slide 30: ZF874 potential disease-modifying treatment for AATD
ZF874 has the potential to be a disease-modifying treatment for AATD 30 • ZF874 is designed to bind to the stalled folding intermediate specific to Z-A1AT with no detectable binding to fully folded Z-A1AT in vitro DESIGNED AS A CATALYTIC, NON-COVALENT SMALL MOLECULE FOLDING CORRECTOR • Initial ZF874
Slide 31: Low doses of ZF874 clear polymer and reduce fibrosis
31 ZF874-treated 54 mpk/day (HED 7 mpk/day) Vehicle Z-A1AT polymer (PAS-D staining) Fibrosis (Sirius Red staining) Liver histology from 84-day treatment of mice expressing human Z-A1AT (PiZ mice) Abbreviations: mpk = milligrams per kilogram; PAS-D = Periodic Acid-Schiff staining with diastase; HED =
Slide 32: Clinical data in PiMZ subjects with placebo or ZF874
Clinical data in PiMZ subjects dosed with placebo or ZF874 15 mpk BID 32 * Activity level equivalent to molar amount of M A1AT reference standard. Baseline for each subject = average of Pre-Screen , Day -1, and Day 1 Pre-Dose values for each subject † Trapezoidal AUC for the first 12 hours after the
Slide 33: Liver signal in one PiMZ subject with highest exposure
Liver signal in one PiMZ subject with highest exposure in Part B 0 100 200 300 400 500 600 700 -21 -14 -7 0 7 14 21 28 35 42 49 56 63 70 33 ALT (IU/L) Time after 1st dose (days) Treatment period ULN ♂ (70 IU/L) Subject 2002 ♂ Placebo Subject 2003 ♀ AUC0-12hr 181 µg·hr/ml Subject 2001 ♂ AUC0-12hr 350
Slide 34: Overview of ongoing Phase 1 trial of ZF874 in AATD
34 Overview of ongoing Phase 1 trial of ZF874 in AATD 1. Morning doses given in the fasted state. Evening doses given after an evening meal Note: 2 subjects received placebo in each cohort for Cohorts 1-6 and none in Cohort 7 15 mg/kg, fed Part A, Cohort 7 (n=6)25 mg/kg BID(1) Part A, Cohort 6 (n=8)
Slide 35: MGX292 in PAH
MGX292 in PAH 35
Slide 36: MGX292 potential for disease reversal in PAH
MGX292 has the potential for disease reversal / modification in PAH 36 • Recombinant modified BMP9 replacement protein designed to directly target BMPR2/ALK1 pathway vs. experimental therapies which inhibit Activin signaling with only indirect effects on this pathway DESIGNED TO DIRECTLY TARGET CENT
Slide 37: MGX292 designed to target central disease mechanism
MGX292 is designed to directly target central underlying disease mechanism 37 In PAH, reduced BMP9 signaling results in the pathological changes underlying PAH. With MGX292 treatment, supplementation with exogenous recombinant BMP9 protein (MGX292) leads to restored signaling and normalization of en
Slide 38: MGX292 reversal of lung vascular pathology in rat model
MGX292 demonstrated dose-dependent reversal of established lung vascular pathology in Sugen-hypoxia rat model MGX2921 reversed neointimal lesions in Sugen-hypoxia rat model of severe PAH 0 5 10 15 20 Normoxic vehicle 3 weeks vehicle 7 weeks vehicle BMP9 (10µg/kg) MGX292 (3µg/kg) MGX292 (10µg/kg) MGX
Slide 39: Development plan for MGX292 in PAH
Development plan for MGX292 in PAH Preclinical development ongoing, currently in the IND-enabling stage Plan to conduct pre-IND meeting with the FDA in the second half of 2022 Plan to submit an IND for MGX292 in early 2023 39
Slide 40: OX2R Agonists in NT1
40 OX2R Agonists in NT1
Slide 41: Orexin agonist approaches to change standard of care in narcolepsy
Our novel orexin agonist approaches have the potential to change the global standard of care in narcolepsy 41 • Lead molecules are designed to selectively target the Orexin Receptor-2 (OX2R) based on structure- based drug design DESIGNED TO DIRECTLY TARGET UNDERLYING PATHOPHYSIOLOGY OF DISEASE • Obs
Slide 42: Small molecule and peptide orexin agonists for replacement therapy
Our small molecule and peptide orexin agonists are designed to provide a potential replacement therapy approach in NT1 42 Example X-ray structure of OX2R with small molecule orexin agonist (shown in purple) Example Cryo-EM structure of OX2R with peptide agonist (shown in purple) Our small molecule a
Slide 43: Orexin agonists increase wakefulness in mice
Novel small molecule and peptide orexin agonists demonstrated dose- dependent effects in increasing wakefulness in mice Exemplar small molecule agonists Exemplar peptide agonist Wakefulness detected by piezoelectric monitoring, which is a rapid, non-invasive method for classifying sleep and wakefuln
Slide 44: Development plan for orexin agonists in NT1
Development plan for orexin agonists in NT1 Plan to submit IND / CTA for lead oral program in 2023 Plan to submit IND / CTA for intranasal program in 2023 Intend to explore additional indications beyond NT1 44
Slide 45: Centessa: assets, resources and talent to drive patient impact
Centessa: the assets, resources and talent to drive patient impact 45 • Exciting pipeline of rare disease programs, led by Registrational programs lixivaptan (ADPKD) and SerpinPC (Hemophilia), and a potential multi-product IO franchise driven by LockBody® programs Substantial product portfolio targe
Slide 46: Centessa Pharmaceuticals
x CENTESSA PHARMACEUTICALS
Centessa Pharmaceuticals — Investor Presentation (March 2022) on 6ix